The value of the assessment of interleukin-6 (IL-6), matrix metalloproteinases and their inhibitors in serum in the assessment of rheumatoid arthritis activity;Przydatność oznaczania w surowicy krwi stȩż eń interleukiny 6 (IL-6), metaloproteinaz i ich tkankowych inhibitorów w ocenie aktywności reumatoidalnego zapalenia stawów

Reumatologia

Volumn 43, Issue 5, 2005, Pages 239-242

  Klimiuk, Piotr Adrian ^a   Sierakowski, Stanisław ^a   Gindzienska Sieskiewicz, Ewa ^a   Chwiećko, Justyna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Interleukin 6; Metalloproteinases; Rheumatoid arthritis; Tissue inhibitors of metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOCONCENTRATION; HUMAN; JOINT; MALE; MEASUREMENT; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

EID: 28244483821     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26: 717-19.
2. van den Berg WB, van Lent PL. The role of macrophages in chronic arthritis. Immunobiology 1996; 195: 614-23.
3. Bernacka K, Sierakowski S, Lachowicz M i wsp. Próba korelacji stȩżenia rodników hydroksylowych w ocenie dwualdehydu malonowego ze stȩżeniem IL-1β, IL-6 i TNFα w surowicy pacjentów z reumatoidalnym zapaleniem stawów. Reumatologia 1996; 34: 15-20.
4. Klimiuk PA, Sierakowski S. Cytokiny w reumatoidalnym zapaleniu stawów. I. Cytokiny prozapalne. Pol Merk Lek 2001; 11: 510-13.
5. Olszewski WL, Pazdur J, Kubasiewicz E, et al. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum 2001; 44: 541-9.
6. Sierakowski S, Bernacka K, Lachowicz M, et al. Concentrations of IL-6 and TNFα in the serum of patients with rheumatoid arthritis in the course of disease. Reumatologia 1996; 34: 184-90.
7. Suffredini AF, Fantuzzi C, Badolato R, et al. New insights into the biology of the acute phase response. J Clin Immunol 1999; 19: 203-14.
8. Dinant HJ, Dijkmans BAC. New therapeutic targets for rheumatoid arthritis. Pharm World Sci 1999; 21: 49-59.
9. Jikko A, Wakisaka T, Iwamoto M, et al. Effects of interleukin-6 on proliferation and proteoglycan metabolism in articular chondrocyte cultures. Cel Biol Int 1998; 22: 615-21.
10. Klimiuk PA, Sierakowski S. Cytokiny i ich antagoniści w leczeniu reumatoidalnego zapalenia stawów. Przegl Lek 2002; 59: 108-12.
11. Nagase H, Okada Y. Proteinases and matrix degradation. In: Textbook of rheumatology. Kelley WN, Harris ED, Ruddy S, et al. (eds). W. B. Saunders Company, Philadelphia 1997; 323-41.
12. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Textbook of rheumatology. Kelley WN, Harris ED, Ruddy S, et al. (eds). W. B. Saunders Company, Philadelphia 1997; 851-97.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: 393-406.
15. Abbas AK, Lichtman AH, Pober JS. Cytokines. In: Cellular and molecular immunology. Abbas AK, Lichtman AH, Pober JS (eds). W. B. Saunders Company, Philadelphia 1994; 240-60.
16. Klimiuk PA, Sierakowski S, Latosiewicz R, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology (Oxford) 2002; 41: 78-87.
17. Klimiuk PA, Yang H, Goronzy JJ, et al. Production of cytokines and metalloproteinases in rheumatoid arthritis is T cell dependent. Clin Immunol 1999; 90: 65-78.
18. Klimiuk PA, Sierakowski S, Chwiecko J. Stȩżenie interleukiny 6 (IL-6) w surowicy koreluje ze stȩżeniem metaloproteinaz i ich tkankowych inhibitorów w reumatoidalnym zapaleniu stawów. Pol Arch Med Wewn 2003; 109: 119-23.
19. Franke S, Herrmann D, Hein G, et al. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy. Eur J Med Res 1997; 29: 401-6.
20. Houssiau FA, Devogelaer J, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8.
21. van Leeuwen MA, Westra J, Limburg PC, et al. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 1995; 54: 33-8.
22. Ichikawa Y, Yamada C, Horiki T, et al. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol 1998; 16: 533-40.
23. Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999; 26: 251-8.
24. So A, Chamot AM, Peclat V, et al. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology 1999; 38: 407-10.